{"id":147460,"date":"2025-09-16T23:03:29","date_gmt":"2025-09-16T21:03:29","guid":{"rendered":"https:\/\/www.startupbusiness.it\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/"},"modified":"2025-09-17T10:26:06","modified_gmt":"2025-09-17T08:26:06","slug":"genoskin-raises-e8-million-for-its-drug-testing-platform","status":"publish","type":"post","link":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/","title":{"rendered":"Genoskin raises \u20ac8 million for its drug testing platform"},"content":{"rendered":"\n

Genoskin, a French-American company operating as a contract research organisation (CRO) that develops ex vivo human skin platforms capable of testing injectable drugs and implantable medical devices, has announced that it has raised $8.7 million (\u20ac8 million) in its first round of funding.<\/strong><\/p>\n\n

In addition to providing a unique and relevant alternative to animal testing for humans, Genoskin models generate large-scale datasets through multi-omic approaches, which are further analysed using artificial intelligence and advanced bioinformatics to provide meaningful insights into the toxicity and efficacy of products tested on humans. The investment round, led by OCCTE (FPCI Occidev Impacts), together with Captech Sant\u00e9, GSO Innovation and CA Toulouse 31 Initiatives (CAT31i), includes $5.4 million (\u20ac5 million) in equity investment. In addition, there is $3.3 million (\u20ac3 million) in non-dilutive financing in the form of structured bank debt, provided by Bpifrance and local banking partners: BNP Paribas, Caisse d’Epargne Midi-Pyr\u00e9n\u00e9es and Cr\u00e9dit Agricole. <\/strong><\/p>\n\n

The funding will fuel Genoskin’s next phase of growth and support the hiring of new staff, with the goal of doubling the size of the company within the next three years and expanding Genoskin’s commercial presence in key global markets. This will include strategic new hires in Europe and Asia by 2026. Genoskin plans to launch new immune system-focused services by 2027 and strengthen its scientific and regulatory position with the development of biosimulation platforms and new human immune models to reduce reliance on animal testing. <\/p>\n\n

Genoskin will also expand its operations through industrial automation and increased production capacity in both the United States and France, moving into its two upgraded and expanded facilities: in Salem, Massachusetts (700 square metres) in 2026 and in Toulouse, France (1,000 square metres) in 2027. This will enable it to double its production of skin models and begin manufacturing fresh human primary mast cells for next-day delivery in the United States. <\/p>\n\n

This funding provides Genoskin with the resources to expand globally, strengthen our presence in key markets, and accelerate the development of our innovative platforms. As a company founded on ethical innovation, we are proud to offer sustainable and human-relevant alternatives to animal testing. This investment confirms our strategy and strengthens our position as a leader in predictive immunotoxicology using living human skin models, said Pascal Descargues, CEO of Genoskin, in a statement (pictured) \u2013 With the support of our investors, Genoskin is ideally positioned to drive meaningful change in how biotherapies are developed, ultimately delivering safer treatments to patients worldwide.”<\/strong><\/p>\n\n

The non-clinical testing market is undergoing a significant transformation. Demand for alternative testing models is expected to grow from $108.6 billion in 2025 to $155.4 billion by 2034, with a CAGR of 4.1%, the company reports in a statement. At the same time, biotech and pharmaceutical companies are facing increasing international pressure from regulatory bodies to reduce or eliminate animal testing, creating a clear demand for ethical alternatives. <\/p>\n\n

Genoskin addresses this need with its scalable and sustainable alternative to animal testing. Using donated human skin and its proprietary preservation technology, the company provides live, immunocompetent ex vivo platforms that remain viable for up to seven days after surgery, enabling more predictive and human-relevant testing than traditional animal or engineered models. Backed by a robust intellectual property portfolio, an established tissue sourcing network, and a scalable, proven service model, Genoskin’s solutions provide human-relevant translational insights that improve predictability and regulatory acceptance. This combination gives Genoskin a unique competitive advantage in providing models that reflect human physiology to biopharmaceutical, cosmetic, and cellular and genetic companies, particularly for skin-related routes of administration, such as injectables, including vaccines and topically administered therapies. <\/p>\n\n

\u201cWe are proud to support Genoskin, a company that perfectly embodies our mission to invest in local innovators who provide sustainable solutions with global reach. Genoskin’s technology offers an ethical and scalable alternative to animal testing and pursues a growth strategy that is strongly aligned with our values of economic resilience and scientific impact,\u201d says Julien Gomis, managing partner at OCCTE.<\/strong><\/p>\n\n

\u201cCaptech Sant\u00e9 is delighted to contribute to the financing of Genoskin, a company capable of setting new global standards in the development of injectable drugs and which already counts most of the world’s leading pharmaceutical companies among its customers,\u201d adds Alexandre Demailly, investor at Captech Sant\u00e9.<\/strong><\/p>\n\n

As part of this round, the following individuals join the Genoskin Board of Directors: Julien Gomis (OCCTE), Alexandre Demailly (Captech Sant\u00e9), Emmanuelle Ostiari (OCCTE) and Ana\u00efs Raluy (GSO\/CAT31i).<\/p>\n","protected":false},"excerpt":{"rendered":"

The Franco-American company’s innovation eliminates the need for animal testing and is ideal for injectable drugs <\/p>\n","protected":false},"author":125,"featured_media":147452,"comment_status":"open","ping_status":"open","sticky":true,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1317],"tags":[1350,2236,1143,1136,1145],"companies":[2907],"journalist":[1518],"class_list":["post-147460","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-funding-news","tag-biotech-en","tag-europa-en","tag-investments","tag-startup-en-2","tag-venture-capital-en-2","companies-genoskin-en","journalist-editorial-staff-en"],"featured_sizes_urls":{"thumbnail":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","width":150,"height":100,"crop":false,"srcset":false,"alt":"test medicali"},"large":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","width":1024,"height":684,"crop":false,"srcset":false,"alt":"test medicali"},"2048x2048":{"src":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","width":2048,"height":1367,"crop":false,"srcset":false,"alt":"test medicali"}},"acf":[],"yoast_head":"\nGenoskin raises \u20ac8 million for its drug testing platform<\/title>\n<meta name=\"description\" content=\"The Franco-American company's innovation eliminates the need for animal testing and is ideal for injectable drugs.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Genoskin raises \u20ac8 million for its drug testing platform\" \/>\n<meta property=\"og:description\" content=\"The Franco-American company's innovation eliminates the need for animal testing and is ideal for injectable drugs.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/\" \/>\n<meta property=\"og:site_name\" content=\"Startupbusiness.it\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-16T21:03:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-09-17T08:26:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1709\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Emil Abirascid\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@emilabirascid\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Emil Abirascid\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/\"},\"author\":{\"name\":\"Emil Abirascid\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"headline\":\"Genoskin raises \u20ac8 million for its drug testing platform\",\"datePublished\":\"2025-09-16T21:03:29+00:00\",\"dateModified\":\"2025-09-17T08:26:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/\"},\"wordCount\":733,\"commentCount\":0,\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Pascal-Descargues-4858-scaled-1.webp\",\"keywords\":[\"biotech\",\"Europa\",\"investments\",\"startup\",\"venture capital\"],\"articleSection\":[\"Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/\",\"name\":\"Genoskin raises \u20ac8 million for its drug testing platform\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Pascal-Descargues-4858-scaled-1.webp\",\"datePublished\":\"2025-09-16T21:03:29+00:00\",\"dateModified\":\"2025-09-17T08:26:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\"},\"description\":\"The Franco-American company's innovation eliminates the need for animal testing and is ideal for injectable drugs.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/genoskin-raises-e8-million-for-its-drug-testing-platform\\\/147460\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Pascal-Descargues-4858-scaled-1.webp\",\"contentUrl\":\"https:\\\/\\\/www.startupbusiness.it\\\/wp-content\\\/uploads\\\/2025\\\/09\\\/Pascal-Descargues-4858-scaled-1.webp\",\"width\":2560,\"height\":1709,\"caption\":\"test medicali\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/\",\"name\":\"Startupbusiness.it\",\"description\":\"May the Force be with you!\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/#\\\/schema\\\/person\\\/4e2760db2cb7ca47d635ea3d8d8486dd\",\"name\":\"Emil Abirascid\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g\",\"caption\":\"Emil Abirascid\"},\"description\":\"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.\",\"sameAs\":[\"https:\\\/\\\/www.abirascid.com\\\/\",\"https:\\\/\\\/www.linkedin.com\\\/in\\\/emilabirascid\",\"https:\\\/\\\/x.com\\\/emilabirascid\"],\"url\":\"https:\\\/\\\/www.startupbusiness.it\\\/en\\\/author\\\/emil-abirascid\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Genoskin raises \u20ac8 million for its drug testing platform","description":"The Franco-American company's innovation eliminates the need for animal testing and is ideal for injectable drugs.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/","og_locale":"en_US","og_type":"article","og_title":"Genoskin raises \u20ac8 million for its drug testing platform","og_description":"The Franco-American company's innovation eliminates the need for animal testing and is ideal for injectable drugs.","og_url":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/","og_site_name":"Startupbusiness.it","article_published_time":"2025-09-16T21:03:29+00:00","article_modified_time":"2025-09-17T08:26:06+00:00","og_image":[{"width":2560,"height":1709,"url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","type":"image\/webp"}],"author":"Emil Abirascid","twitter_card":"summary_large_image","twitter_creator":"@emilabirascid","twitter_misc":{"Written by":"Emil Abirascid","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/#article","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/"},"author":{"name":"Emil Abirascid","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"headline":"Genoskin raises \u20ac8 million for its drug testing platform","datePublished":"2025-09-16T21:03:29+00:00","dateModified":"2025-09-17T08:26:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/"},"wordCount":733,"commentCount":0,"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","keywords":["biotech","Europa","investments","startup","venture capital"],"articleSection":["Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/","url":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/","name":"Genoskin raises \u20ac8 million for its drug testing platform","isPartOf":{"@id":"https:\/\/www.startupbusiness.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/#primaryimage"},"image":{"@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/#primaryimage"},"thumbnailUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","datePublished":"2025-09-16T21:03:29+00:00","dateModified":"2025-09-17T08:26:06+00:00","author":{"@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd"},"description":"The Franco-American company's innovation eliminates the need for animal testing and is ideal for injectable drugs.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.startupbusiness.it\/en\/genoskin-raises-e8-million-for-its-drug-testing-platform\/147460\/#primaryimage","url":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","contentUrl":"https:\/\/www.startupbusiness.it\/wp-content\/uploads\/2025\/09\/Pascal-Descargues-4858-scaled-1.webp","width":2560,"height":1709,"caption":"test medicali"},{"@type":"WebSite","@id":"https:\/\/www.startupbusiness.it\/en\/#website","url":"https:\/\/www.startupbusiness.it\/en\/","name":"Startupbusiness.it","description":"May the Force be with you!","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.startupbusiness.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.startupbusiness.it\/en\/#\/schema\/person\/4e2760db2cb7ca47d635ea3d8d8486dd","name":"Emil Abirascid","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/84e46190ac811c9c62650621ceca8f65c1e967d6b06e6352fe183145dba0d7e9?s=96&d=mm&r=g","caption":"Emil Abirascid"},"description":"Emil Abirascid (\u30a8\u30df\u30fc\u30eb\u30fb\u30a2\u30d3\u30e9\u30b7\u30c3\u30c9), giornalista, fondatore e direttore di Startupbusiness, il primo magazine sull\u2019ecosistema startup e innovazione italiano. Co-fondatore di Designtech, l\u2019hub di innovazione che avvicina il mondo del design con quello della tecnologia. Advisor di Austrian Business Agency, Emil Banca, Fondazione Symbola, Fondazione Quadrans. Partecipa regolarmente a incontri, convegni, conferenze dedicate all\u2019ecosistema dell\u2019innovazione. E\u2019 stato co-organizzatore degli Italian Innovation Day and Series che si sono svolti dal dal 2016 al 2020 nelle citt\u00e0 di Tokyo in Giappone, Melbourne, Adelaide, Perth, Canberra in Australia e Singapore e co-organizzatore dell\u2019Italy India Innovation Day di AIICP 2021 e 2022. Ha curato il volume \u2018L\u2019innovazione che non ti aspetti. Contesti e visioni per l\u2019impresa\u2019 , l\u2019edizione italiana di \u2018La startup digitale, guida pratica step by step\u2019 e ha scritto la prefazione all\u2019edizione italiana de \u2018La quarta era\u2019 di Byron Reese, ed \u00e8 co-autore di \u2018Cosa e Dove: strategie digitali di ricerca del lavoro\u2019, tutti editi da FrancoAngeli. In passato \u00e8 stato curatore di StartupDigest Italy, coordinatore scientifico del Forum per la Ricerca della Provincia Autonoma di Trento, board member di TechChill Milano advisor di di ScaleIT , ha collaborato con Il Sole 24 Ore \u00e8 stato direttore di Innov\u2019azione, bimestrale edito da Apsti, ha collaborato con Corriere Innovazione ed \u00e8 stato presidente del comitato di selezione del Premio Marzotto e advisor di Cetif-Universit\u00e0 Cattolica Milano.","sameAs":["https:\/\/www.abirascid.com\/","https:\/\/www.linkedin.com\/in\/emilabirascid","https:\/\/x.com\/emilabirascid"],"url":"https:\/\/www.startupbusiness.it\/en\/author\/emil-abirascid\/"}]}},"author_name":"Emil Abirascid","categories_names":["Funding News"],"_links":{"self":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/147460","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/comments?post=147460"}],"version-history":[{"count":1,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/147460\/revisions"}],"predecessor-version":[{"id":147461,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/posts\/147460\/revisions\/147461"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media\/147452"}],"wp:attachment":[{"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/media?parent=147460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/categories?post=147460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/tags?post=147460"},{"taxonomy":"companies","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/companies?post=147460"},{"taxonomy":"journalist","embeddable":true,"href":"https:\/\/www.startupbusiness.it\/en\/wp-json\/wp\/v2\/journalist?post=147460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}